The Giant Cell Tumor Of Bone drugs in development market research report provides comprehensive information on the therapeutics under development for Giant Cell Tumor Of Bone, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Giant Cell Tumor Of Bone. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Giant Cell Tumor Of Bone and features dormant and discontinued products.
GlobalData tracks 11 drugs in development for Giant Cell Tumor Of Bone by 11 companies/universities/institutes. The top development phase for Giant Cell Tumor Of Bone is phase i with three drugs in that stage. The Giant Cell Tumor Of Bone pipeline has 11 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Giant Cell Tumor Of Bone pipeline products market are: Jiangsu Hansoh Pharmaceutical Group, Genor BioPharma and Eden Biologics.
The key targets in the Giant Cell Tumor Of Bone pipeline products market include Tumor Necrosis Factor Ligand Superfamily Member 11, and Tumor Necrosis Factor Receptor Superfamily Member 11A.
The key mechanisms of action in the Giant Cell Tumor Of Bone pipeline product include Tumor Necrosis Factor Ligand Superfamily Member 11 Inhibitor with nine drugs in Pre-Registration. The Giant Cell Tumor Of Bone pipeline products include two routes of administration with the top ROA being Subcutaneous and two key molecule types in the Giant Cell Tumor Of Bone pipeline products market including Monoclonal Antibody, and Cell Therapy.
Giant Cell Tumor Of Bone overview
Giant Cell Tumor is a common benign tumor (non-cancerous) that grows at the long bones typically femur and tibia and knee joints. It is observed commonly in age groups 20-40 years. As name reflects the tumor cells appears giant in size. It can be aggressive and may spread to the surrounding bones in rare cases. Cause is unknown. But mutations on H3F3A gene believed to be a cause and RANKL gene highly expressed on these giant cells and is a therapeutic target for the treatment. Pain, swelling, deformity, bump, synovitis are the common symptoms. X-rays, CT scan are the common diagnostic parameters. Bisphosphonates orally or topically, monoclonal antibodies, radiotherapy and surgical therapy are treatment options.
For a complete picture of Giant Cell Tumor Of Bone’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
